Detecting endometrial cancer by blood spectroscopy: A diagnostic cross-sectional study

Maria Paraskevaidi; Camilo L.M. Morais; Katherine Ashton; Helen Stringfellow; Rhona J McVey; Neil Ryan; Helena O'Flynn; Vanitha Sivalingam; Sarah Kitson; Michelle Mackintosh; Abigail Derbyshire; Cecilia Pow; Olivia Raglan; Kassio M. G. Lima; Maria Kyrgiou; Pierre L. Martin-Hirsch; Francis Martin; Emma Crosbie

doi:10.3390/cancers12051256

Detecting endometrial cancer by blood spectroscopy: A diagnostic cross-sectional study

Maria Paraskevaidi, Camilo L.M. Morais, Katherine Ashton, Helen Stringfellow, Rhona J McVey, Neil Ryan, Helena O'Flynn, Vanitha Sivalingam, Sarah Kitson, Michelle Mackintosh, Abigail Derbyshire, Cecilia Pow, Olivia Raglan, Kassio M. G. Lima, Maria Kyrgiou, Pierre L. Martin-Hirsch, Francis Martin, Emma Crosbie

Research output: Contribution to journal › Article › peer-review

Abstract

Endometrial cancer is the sixth most common cancer in women with a rising incidence worldwide. Current approaches for the diagnosis and screening of endometrial cancer are invasive, expensive and of moderate diagnostic accuracy, limiting their clinical utility. There is a need for cost-effective and minimally invasive biomarkers to facilitate the early detection and timely management of endometrial cancer.

We analysed blood plasma samples in a cross-sectional diagnostic accuracy study of women with endometrial cancer (n=342), its precursor lesion atypical hyperplasia (n=68) and healthy controls (n=242, total n=652) using attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy and machine learning algorithms.

We show that blood-based infrared spectroscopy has the potential to detect endometrial cancer with 87% sensitivity and 78% specificity. Its accuracy is highest for type I endometrial cancer, the most common subtype, and for atypical hyperplasia, with sensitivities of 91% and 100%, and specificities of 81% and 88%, respectively.

Our large-cohort study shows that a simple blood test could enable the early detection of endometrial cancer of all stages in symptomatic women and provide the basis of a screening tool in high-risk groups. Such a test will not only differentially diagnose endometrial cancer but also detect its precursor lesion atypical hyperplasia, the early recognition of which may allow fertility-sparing management and cancer prevention.

Original language	English
Article number	1256
Journal	Cancers
Volume	12
Issue number	5
DOIs	https://doi.org/10.3390/cancers12051256
Publication status	Published - 16 May 2020

Keywords

blood diagnostics
endometrial cancer
screening
spectroscopy

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers12051256Licence: CC BY

Cite this

Paraskevaidi, M., Morais, C. L. M., Ashton, K., Stringfellow, H., McVey, R. J., Ryan, N., O'Flynn, H., Sivalingam, V., Kitson, S., Mackintosh, M., Derbyshire, A., Pow, C., Raglan, O., Lima, K. M. G., Kyrgiou, M., Martin-Hirsch, P. L., Martin, F., & Crosbie, E. (2020). Detecting endometrial cancer by blood spectroscopy: A diagnostic cross-sectional study. Cancers, 12(5), Article 1256. https://doi.org/10.3390/cancers12051256

@article{912741aa3f3b49d199b3179dd2ffa6df,

title = "Detecting endometrial cancer by blood spectroscopy: A diagnostic cross-sectional study",

abstract = "Endometrial cancer is the sixth most common cancer in women with a rising incidence worldwide. Current approaches for the diagnosis and screening of endometrial cancer are invasive, expensive and of moderate diagnostic accuracy, limiting their clinical utility. There is a need for cost-effective and minimally invasive biomarkers to facilitate the early detection and timely management of endometrial cancer.We analysed blood plasma samples in a cross-sectional diagnostic accuracy study of women with endometrial cancer (n=342), its precursor lesion atypical hyperplasia (n=68) and healthy controls (n=242, total n=652) using attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy and machine learning algorithms.We show that blood-based infrared spectroscopy has the potential to detect endometrial cancer with 87% sensitivity and 78% specificity. Its accuracy is highest for type I endometrial cancer, the most common subtype, and for atypical hyperplasia, with sensitivities of 91% and 100%, and specificities of 81% and 88%, respectively.Our large-cohort study shows that a simple blood test could enable the early detection of endometrial cancer of all stages in symptomatic women and provide the basis of a screening tool in high-risk groups. Such a test will not only differentially diagnose endometrial cancer but also detect its precursor lesion atypical hyperplasia, the early recognition of which may allow fertility-sparing management and cancer prevention.",

keywords = "blood diagnostics, endometrial cancer, screening, spectroscopy",

author = "Maria Paraskevaidi and Morais, {Camilo L.M.} and Katherine Ashton and Helen Stringfellow and McVey, {Rhona J} and Neil Ryan and Helena O'Flynn and Vanitha Sivalingam and Sarah Kitson and Michelle Mackintosh and Abigail Derbyshire and Cecilia Pow and Olivia Raglan and Lima, {Kassio M. G.} and Maria Kyrgiou and Martin-Hirsch, {Pierre L.} and Francis Martin and Emma Crosbie",

year = "2020",

month = may,

day = "16",

doi = "10.3390/cancers12051256",

language = "English",

volume = "12",

journal = "Cancers",

issn = "2072-6694",

publisher = "MDPI",

number = "5",

}

Paraskevaidi, M, Morais, CLM, Ashton, K, Stringfellow, H, McVey, RJ, Ryan, N, O'Flynn, H, Sivalingam, V , Kitson, S, Mackintosh, M, Derbyshire, A, Pow, C, Raglan, O, Lima, KMG, Kyrgiou, M, Martin-Hirsch, PL, Martin, F & Crosbie, E 2020, 'Detecting endometrial cancer by blood spectroscopy: A diagnostic cross-sectional study', Cancers, vol. 12, no. 5, 1256. https://doi.org/10.3390/cancers12051256

TY - JOUR

T1 - Detecting endometrial cancer by blood spectroscopy: A diagnostic cross-sectional study

AU - Paraskevaidi, Maria

AU - Morais, Camilo L.M.

AU - Ashton, Katherine

AU - Stringfellow, Helen

AU - McVey, Rhona J

AU - Ryan, Neil

AU - O'Flynn, Helena

AU - Sivalingam, Vanitha

AU - Kitson, Sarah

AU - Mackintosh, Michelle

AU - Derbyshire, Abigail

AU - Pow, Cecilia

AU - Raglan, Olivia

AU - Lima, Kassio M. G.

AU - Kyrgiou, Maria

AU - Martin-Hirsch, Pierre L.

AU - Martin, Francis

AU - Crosbie, Emma

PY - 2020/5/16

Y1 - 2020/5/16

N2 - Endometrial cancer is the sixth most common cancer in women with a rising incidence worldwide. Current approaches for the diagnosis and screening of endometrial cancer are invasive, expensive and of moderate diagnostic accuracy, limiting their clinical utility. There is a need for cost-effective and minimally invasive biomarkers to facilitate the early detection and timely management of endometrial cancer.We analysed blood plasma samples in a cross-sectional diagnostic accuracy study of women with endometrial cancer (n=342), its precursor lesion atypical hyperplasia (n=68) and healthy controls (n=242, total n=652) using attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy and machine learning algorithms.We show that blood-based infrared spectroscopy has the potential to detect endometrial cancer with 87% sensitivity and 78% specificity. Its accuracy is highest for type I endometrial cancer, the most common subtype, and for atypical hyperplasia, with sensitivities of 91% and 100%, and specificities of 81% and 88%, respectively.Our large-cohort study shows that a simple blood test could enable the early detection of endometrial cancer of all stages in symptomatic women and provide the basis of a screening tool in high-risk groups. Such a test will not only differentially diagnose endometrial cancer but also detect its precursor lesion atypical hyperplasia, the early recognition of which may allow fertility-sparing management and cancer prevention.

AB - Endometrial cancer is the sixth most common cancer in women with a rising incidence worldwide. Current approaches for the diagnosis and screening of endometrial cancer are invasive, expensive and of moderate diagnostic accuracy, limiting their clinical utility. There is a need for cost-effective and minimally invasive biomarkers to facilitate the early detection and timely management of endometrial cancer.We analysed blood plasma samples in a cross-sectional diagnostic accuracy study of women with endometrial cancer (n=342), its precursor lesion atypical hyperplasia (n=68) and healthy controls (n=242, total n=652) using attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy and machine learning algorithms.We show that blood-based infrared spectroscopy has the potential to detect endometrial cancer with 87% sensitivity and 78% specificity. Its accuracy is highest for type I endometrial cancer, the most common subtype, and for atypical hyperplasia, with sensitivities of 91% and 100%, and specificities of 81% and 88%, respectively.Our large-cohort study shows that a simple blood test could enable the early detection of endometrial cancer of all stages in symptomatic women and provide the basis of a screening tool in high-risk groups. Such a test will not only differentially diagnose endometrial cancer but also detect its precursor lesion atypical hyperplasia, the early recognition of which may allow fertility-sparing management and cancer prevention.

KW - blood diagnostics

KW - endometrial cancer

KW - screening

KW - spectroscopy

U2 - 10.3390/cancers12051256

DO - 10.3390/cancers12051256

M3 - Article

SN - 2072-6694

VL - 12

JO - Cancers

JF - Cancers

IS - 5

M1 - 1256

ER -

Detecting endometrial cancer by blood spectroscopy: A diagnostic cross-sectional study

Abstract

Keywords

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Fingerprint

Cite this